Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SYS003
MIFTS: 46

Systolic Heart Failure

Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Systolic Heart Failure

About this section

MalaCards integrated aliases for Systolic Heart Failure:

Name: Systolic Heart Failure 12 15
Heart Failure, Systolic 44 73

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9651
ICD10 33 I50.20
ICD9CM 35 428.2 428.20
MeSH 44 D054143
UMLS 73 C1135191
Sources

Summaries for Systolic Heart Failure

About this section
MalaCards based summary : Systolic Heart Failure, also known as heart failure, systolic, is related to mitral valve insufficiency and pulmonary hypertension. An important gene associated with Systolic Heart Failure is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Dilated cardiomyopathy (DCM) and Melatonin metabolism and effects. The drugs Verapamil and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and growth/size/body region

Sources

Related Diseases for Systolic Heart Failure

About this section

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 mitral valve insufficiency 30.7 ACE NPPB
2 pulmonary hypertension 30.6 ACE EDN1 NPPB
3 atrial fibrillation 30.5 ACE ADRB1 CRP NPPB
4 central sleep apnea 30.4 HSPB7 NPPB
5 left bundle branch hemiblock 30.4 ACE NPPB
6 diastolic heart failure 30.3 ACE NPPB
7 arteries, anomalies of 30.3 ACE CRP EDN1 IL6 NPPB
8 sleep apnea 30.2 ACE CRP EDN1 IL6 NPPB
9 coronary artery anomaly 30.0 ACE ADRB1 CRP EDN1 NPPB
10 diabetes mellitus 30.0 ACE CRP EDN1 IL6
11 ischemic heart disease 29.9 ACE CRP IL6 NPPB
12 congestive heart failure 29.9 ACE ADRB1 EDN1 NPPB NR3C2
13 chagas disease 29.9 ACE ADRB1 IL6 NPPB
14 chronic kidney failure 29.9 ACE CRP CST3 EDN1 IL6 NPPB
15 intermittent claudication 29.8 ACE CRP IL6
16 apnea, obstructive sleep 29.8 CRP EDN1 IL6
17 pulmonary disease, chronic obstructive 29.8 CRP IL6 NPPB
18 diabetes mellitus, noninsulin-dependent 29.8 ACE CRP EDN1 IL6
19 acute myocardial infarction 29.7 ACE ADRB1 CRP EDN1 NPPB
20 kidney disease 29.6 ACE CRP CST3 EDN1 IL6 NPPB
21 angina pectoris 29.5 ACE CRP EDN1 IL6 NPPB
22 heart disease 29.3 ACE ADRB1 CRP CST3 EDN1 IL6
23 myocardial infarction 29.1 ACE ADRB1 CRP CST3 EDN1 IL6
24 dilated cardiomyopathy 28.8 ACE ADRB1 CRP EDN1 HSPB7 IL6
25 peripartum cardiomyopathy 11.1
26 body mass index quantitative trait locus 1 10.3
27 anterolateral myocardial infarction 10.3 ACE NPPB
28 depression 10.2
29 chronic mountain sickness 10.2 EDN1 NPPB
30 syndrome of inappropriate antidiuretic hormone 10.2 ACE NPPB
31 cardiogenic shock 10.2 IL6 NPPB
32 malignant hypertension 10.2 ACE EDN1
33 aortic valve insufficiency 10.2 ACE NPPB
34 posterior urethral valves 10.2 ACE IL6
35 meconium aspiration syndrome 10.2 EDN1 IL6
36 sexual disorder 10.2 ACE EDN1
37 mesangial proliferative glomerulonephritis 10.2 EDN1 IL6
38 ischemic optic neuropathy 10.2 ACE EDN1
39 retinal artery occlusion 10.2 ACE IL6
40 anuria 10.2 ACE NR3C2
41 generalized atherosclerosis 10.2 ACE CRP
42 renovascular hypertension 10.2 ACE EDN1
43 renal hypertension 10.1 ACE EDN1 NPPB
44 cold agglutinin disease 10.1 CRP IL6
45 oligohydramnios 10.1 ACE EDN1 NPPB
46 cryopyrin-associated periodic syndrome 10.1 CRP IL6
47 subdural empyema 10.1 ACE CRP
48 acute cholangitis 10.1 CRP IL6
49 hypersensitivity vasculitis 10.1 ACE CRP
50 uremic pruritus 10.1 CRP IL6

Graphical network of the top 20 diseases related to Systolic Heart Failure:



Diseases related to Systolic Heart Failure
Sources

Symptoms & Phenotypes for Systolic Heart Failure

About this section

MGI Mouse Phenotypes related to Systolic Heart Failure:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 ACE ADRB1 CORIN CRP CST3 EDN1
2 growth/size/body region MP:0005378 9.86 ACE ADRB1 CORIN EDN1 HSPB7 IL6
3 homeostasis/metabolism MP:0005376 9.85 ACE ADRB1 CORIN CRP CST3 EDN1
4 muscle MP:0005369 9.5 ADRB1 CORIN CST3 EDN1 HSPB7 IL6
5 renal/urinary system MP:0005367 9.1 ACE CORIN EDN1 IL6 LGALS3 NR3C2
Sources

Drugs & Therapeutics for Systolic Heart Failure

About this section

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verapamil Approved Phase 4 52-53-9 2520
2
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
3
Ticlopidine Approved Phase 4 55142-85-3 5472
4
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
5
Bisoprolol Approved Phase 4 66722-44-9 2405
6
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
7
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Angiotensin II Approved, Investigational Phase 4,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
10
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
11
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
12
Enalaprilat Approved Phase 4 76420-72-9 6917719
13
Canagliflozin Approved Phase 4 842133-18-0
14
Nitric Oxide Approved Phase 4 10102-43-9 145068
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
16
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
17 Angiotensin Receptor Antagonists Phase 4
18 Adrenergic beta-Antagonists Phase 4,Phase 1,Not Applicable
19 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 2
20 Adrenergic alpha-1 Receptor Antagonists Phase 4
21 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Adrenergic alpha-Antagonists Phase 4
23 Adrenergic Antagonists Phase 4,Not Applicable
24 Anti-Arrhythmia Agents Phase 4,Not Applicable
25 Calcium, Dietary Phase 4,Phase 3
26 Adrenergic Agents Phase 4,Phase 1,Not Applicable
27 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
28 calcium channel blockers Phase 4
29 Antihypertensive Agents Phase 4,Phase 2,Not Applicable
30 Hormones Phase 4,Phase 3,Phase 1
31 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2
32 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
33 Prasugrel hydrochloride Phase 4 389574-19-0
34 Purinergic P2 Receptor Antagonists Phase 4
35 Fibrinolytic Agents Phase 4
36 Platelet Aggregation Inhibitors Phase 4
37 Cytochrome P-450 CYP2C19 Inhibitors Phase 4
38 Purinergic P2Y Receptor Antagonists Phase 4
39 Autonomic Agents Phase 4,Not Applicable
40 Sympatholytics Phase 4,Not Applicable
41 Peripheral Nervous System Agents Phase 4,Not Applicable
42 Adrenergic beta-1 Receptor Antagonists Phase 4,Not Applicable
43 Angiotensin II Type 1 Receptor Blockers Phase 4
44 HIV Protease Inhibitors Phase 4,Phase 2
45
protease inhibitors Phase 4,Phase 2
46 Angiotensinogen Phase 4,Phase 2
47 Vitamin B Complex Phase 4,Phase 1,Phase 2
48 Thiamin Phase 4
49 Vitamin B9 Phase 4,Phase 1,Phase 2
50 Vitamins Phase 4,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
2 Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Unknown status NCT00541268 Phase 4
3 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
4 Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
5 Danish ICD Study in Patients With Dilated Cardiomyopathy Unknown status NCT00542945 Phase 4
6 Platelet Inhibition in Patients With Systolic Heart Failure Completed NCT01765400 Phase 4 Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks
7 Medtronic South Asian Systolic Heart Failure Registry Completed NCT01434615 Phase 4
8 A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
9 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
10 Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure Completed NCT02401126 Phase 4
11 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
12 A Trial of Thiamin Supplementation in Patients With Heart Failure Completed NCT00959075 Phase 4
13 A Study Of The Usage Of Statins In A Community Heart Failure Population Completed NCT00795912 Phase 4 Atorvastatin
14 Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting Completed NCT02690974 Phase 4 LCZ696 (sacubitril/valsartan)
15 Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations Recruiting NCT03764722 Phase 4 Levosimendan
16 Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality Recruiting NCT03036462 Phase 4 Iron;Saline
17 Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF) Recruiting NCT03096613 Phase 4 Levothyroxine
18 Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Recruiting NCT02768298 Phase 4 LCZ696;enalapril;Enalapril matching placebo;LCZ696 matching placebo
19 Treatment of Diabetes in Patients With Systolic Heart Failure Active, not recruiting NCT02920918 Phase 4 Canagliflozin;Sitagliptin
20 Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Withdrawn NCT02767024 Phase 4 Sodium nitroprusside;Dobutamine;Furosemide
21 Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST） Unknown status NCT02188082 Phase 2, Phase 3 IvabRadine hemisulfate Sustained-release Tablets;placebo
22 Renal Artery Denervation in Chronic Heart Failure Study Unknown status NCT01639378 Phase 3
23 Imaging Study of Allocation of Pacing Targets in Cardiac Resynchronization Therapy Unknown status NCT01640769 Phase 3
24 Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction Unknown status NCT00497211 Phase 2, Phase 3
25 Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Completed NCT02998697 Phase 2, Phase 3 Ferrous Sulfate;Placebo Oral Capsule
26 Spinal Cord Stimulation For Heart Failure Completed NCT01362725 Phase 2, Phase 3
27 Crestor Versus Placebo in Subjects With Heart Failure Completed NCT00206310 Phase 3 CRESTOR
28 A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines Completed NCT00232180 Phase 3 Eplerenone
29 ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Completed NCT00111969 Phase 3
30 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD Completed NCT01754259 Phase 3 Ranolazine;Placebo
31 A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure. Completed NCT00270374 Phase 3 nesiritide
32 Cardiovascular Effects of Preferred Home-based Exercise Training in Systolic Heart Failure Recruiting NCT02051712 Phase 3
33 Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension Recruiting NCT01913847 Phase 3 Sildenafil;Placebo
34 Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients Recruiting NCT03388593 Phase 3 rhNRG-1;Placebo
35 Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
36 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure Terminated NCT01646515 Phase 3 Placebo;Udenafil (Zydena)
37 Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients Terminated NCT01439893 Phase 3 rhNRG-1;Placebo
38 Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure Terminated NCT01214096 Phase 3 rhNRG-1;rhNRG-1;rhNRG-1;placebo
39 Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients Terminated NCT01541202 Phase 3 rhNRG-1;Placebo
40 Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients Terminated NCT01439789 Phase 3 rhNRG-1;Placebo
41 Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients Terminated NCT01131637 Phase 3 rhNRG-1;placebo
42 Effect at 6 Months of Renal Denervation in Chronic Heart Failure d'Insuffisance Cardiaque Unknown status NCT02471729 Phase 1, Phase 2
43 Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure Completed NCT00923156 Phase 2 aliskiren;ramipril;Placebo to aliskiren;Placebo to ramipril
44 Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure Completed NCT01814319 Phase 2 Probenecid 1 gr oral twice daily;Placebo
45 A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure Completed NCT01096043 Phase 2 Placebo;Strata 1 CXL-1020;Strata 2 CXL-1020;Strata 3 CXL-1020
46 A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure Completed NCT02157506 Phase 2 CXL-1427;Placebo
47 Multiple Dose Study in Heart Failure of BAY 1067197 Completed NCT02040233 Phase 2 BAY1067197 (10 mg);BAY1067197;Placebo (10 mg);Placebo
48 Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure Completed NCT01112579 Phase 2
49 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction Completed NCT00387621 Phase 1, Phase 2 Nesiritide;Placebo;Saline
50 Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention? Completed NCT02076711 Phase 2 Metoprololsuccinate;Placebo

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Sources

Genetic Tests for Systolic Heart Failure

About this section
Sources

Anatomical Context for Systolic Heart Failure

About this section

MalaCards organs/tissues related to Systolic Heart Failure:

41
Heart, Testes, Brain, Endothelial, Kidney, Bone, Spinal Cord
Sources

Publications for Systolic Heart Failure

About this section

Articles related to Systolic Heart Failure:

(show top 50) (show all 862)
# Title Authors Year
1
Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine. ( 29896315 )
2018
2
Effect of Early Treatment With Ivabradine Plus Beta-blockers on Long-term Outcomes in Patients Hospitalized With Systolic Heart Failure. ( 29373253 )
2018
3
Response by Elming et al to Letter Regarding Article, "Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure". ( 29760232 )
2018
4
Acute Right Middle Cerebral Artery Occlusion Resulting in Acute Systolic Heart Failure, Cerebral T-Waves, and QTc Prolongation: A Case Report. ( 29953038 )
2018
5
Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. ( 29762337 )
2018
6
Systolic heart failure in a patient with primary aldosteronism. ( 29884668 )
2018
7
Utility of Left Atrial Expansion Index and Stroke Volume in Management of Chronic Systolic Heart Failure. ( 29426648 )
2018
8
Prediction of the ischemic origin of functional mitral regurgitation in patients with systolic heart failure through posterior mitral leaflet angle. ( 29942334 )
2018
9
Comparison of triple-site ventricular pacing versus conventional cardiac resynchronization therapy in patients with systolic heart failure: A meta-analysis of randomized and observational studies. ( 29721114 )
2018
10
Contractile reserve as a predictor of prognosis in patients with non-ischaemic systolic heart failure and dilated cardiomyopathy: a systematic review and meta-analysis. ( 29258998 )
2018
11
Resistance exercise enhances oxygen uptake without worsening cardiac function in patients with systolic heart failure: a systematic review and meta-analysis. ( 29199385 )
2018
12
Echocardiographic Insights into the Hemodynamics of Systolic Heart Failure: Can This Guide Titration of Medical Therapy? ( 29730184 )
2018
13
Dysregulations of miRNAs and galectin-3 may underlie left ventricular dilatation in patients with systolic heart failure. ( 29905365 )
2018
14
Three-dimensional echocardiographic evaluation of mechanical dyssynchrony in systolic heart failure with narrow QRS complex. ( 29961455 )
2018
15
Is There a Sex-Related Difference in the Obesity Paradox in Systolic Heart Failure? Sex-Related Difference in the Obesity Paradox. ( 29214777 )
2018
16
The interaction of QRS duration with cardiac magnetic resonance derived scar and mechanical dyssynchrony in systolic heart failure: Implications for cardiac resynchronization therapy. ( 29750182 )
2018
17
Pulmonary hypertension due to left heart disease: diagnostic and prognostic value of CT in chronic systolic heart failure. ( 29761362 )
2018
18
Hopelessness and cognitive impairment are risk markers for mortality in systolic heart failure patients. ( 29773147 )
2018
19
Has the Time Come to Be More Aggressive With Bariatric Surgery in Obese Patients With Chronic Systolic Heart Failure? ( 29629485 )
2018
20
Accuracy of cardiac magnetic resonance imaging to rule out significant coronary artery disease in patients with systolic heart failure of unknown aetiology: Single-centre experience and comprehensive meta-analysis. ( 29861294 )
2018
21
Systolic heart failure after liver transplantation: Incidence, predictors, and outcome. ( 29323769 )
2018
22
Letter by Adabag et al Regarding Article, "Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure". ( 29760231 )
2018
23
Daily non-invasive haemodynamic telemonitoring for efficacy evaluation of MitraClipAr implantation in patients with advanced systolic heart failure. ( 29893475 )
2018
24
Percutaneous renal artery denervation in patients with chronic systolic heart failure: a randomized controlled trial. ( 29611171 )
2018
25
Safety of Calcium-Channel Blockers During Radial Cardiac Catheterization in Patients With Acute Myocardial Infarction or Systolic Heart Failure. ( 30555053 )
2018
26
Outcomes of patients with systolic heart failure presenting with sepsis to the emergency department of a tertiary hospital: a retrospective chart review study from Lebanon. ( 30068620 )
2018
27
Symptom patterns and clinical outcomes in women versus men with systolic heart failure and depression. ( 30097684 )
2018
28
The Metabolic Syndrome, Cardiovascular Fitness and Survival in Patients With Advanced Systolic Heart Failure. ( 30172361 )
2018
29
Ischemic evaluation in patients presenting with hypertensive emergency / urgency and acute systolic heart failure: Is coronary angiography required for all? ( 30177272 )
2018
30
Prevalence of P wave dispersion and interatrial block in patients with systolic heart failure and their relationship with functional status, hospitalization and one year mortality. ( 30190644 )
2018
31
Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure. ( 30193537 )
2018
32
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. ( 30223365 )
2018
33
Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. ( 30244844 )
2018
34
Association of preexisting hypertension with the morality in patients with systolic heart failure in Taiwan: The TSOC-HFrEF registry. ( 30392495 )
2018
35
Heart filling exceeds emptying during late ventricular systole in patients with systolic heart failure and healthy subjects - a cardiac MRI study. ( 30506862 )
2018
36
Clinical profile and management of outpatients with non-ischemic and non-hypertensive systolic heart failure: Analysis of the Polish DATA-HELP registry. ( 28394012 )
2018
37
Intravascular Volume Profiles in Patients With Class I and II Systolic Heart Failure: Heterogeneity and Volume Overload Are Common Even in Mild Heart Failure. ( 28982634 )
2018
38
Soluble ST2 biomarker and reverse remodelling in patients with systolic heart failure. ( 29455780 )
2018
39
Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients. ( 29460403 )
2018
40
Pathophysiology of Chronic Systolic Heart Failure. A View from the Periphery. ( 29461891 )
2018
41
Ivabradine for systolic heart failure. ( 29470374 )
2018
42
Left atrial dilatation in systolic heart failure: a marker of poor prognosis, not just a buffer between the left ventricle and pulmonary circulation. ( 29476388 )
2018
43
Cryoballoon ablation of atrial fibrillation in patients with advanced systolic heart failure and cardiac implantable electronic devices. ( 29528482 )
2018
44
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. ( 29569494 )
2018
45
Neopterin as a novel marker; well correlated with mortality and morbidity in patients with advanced systolic heart failure. ( 29914304 )
2018
46
Myocardial perfusion during atrial fibrillation in patients with non-ischaemic systolic heart failure: a cross-sectional study using Rubidium-82 positron emission tomography/computed tomography. ( 29992262 )
2018
47
Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. ( 30015405 )
2018
48
Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. ( 30057167 )
2018
49
Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. ( 30067817 )
2018
50
The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study. ( 27865188 )
2017
Sources

Variations for Systolic Heart Failure

About this section
Sources

Expression for Systolic Heart Failure

About this section
Search GEO for disease gene expression data for Systolic Heart Failure.
Sources

Pathways for Systolic Heart Failure

About this section

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Dilated cardiomyopathy (DCM) 37
Show member pathways
 11.57 ACE ADRB1 IL6
2
Melatonin metabolism and effects 1
10.94 ADRB1 EDN1
3
Endothelin Pathways 1
10.85 ADRB1 EDN1
4
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 10.73 CRP EDN1
5
A-beta Pathways: Plaque Formation and APP Metabolism 65
10.32 ACE CST3
6
Overview of nanoparticle effects 1
9.9 CRP IL6
Sources

GO Terms for Systolic Heart Failure

About this section

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ACE CRP CST3 EDN1 IL6 LGALS3
2 extracellular region GO:0005576 9.23 ACE CORIN CRP CST3 EDN1 IL6

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 acute-phase response GO:0006953 9.48 CRP IL6
2 regulation of vasoconstriction GO:0019229 9.46 ACE EDN1
3 regulation of blood vessel size GO:0050880 9.43 EDN1 NPPB
4 positive regulation of renal sodium excretion GO:0035815 9.4 EDN1 NPPB
5 positive regulation of urine volume GO:0035810 9.37 EDN1 NPPB
6 regulation of blood vessel diameter GO:0097746 9.32 ACE NPPB
7 body fluid secretion GO:0007589 9.26 EDN1 NPPB
8 negative regulation of lipid storage GO:0010888 9.16 CRP IL6
9 neutrophil mediated immunity GO:0002446 8.96 ACE IL6
10 regulation of blood pressure GO:0008217 8.92 ACE CORIN EDN1 NPPB
Sources

Sources for Systolic Heart Failure

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....